The diagnostics firm was acquired at great cost, but is unable to support PharmEasy’s core online pharmacy business.
Just a few months ago, it looked like PharmEasy was well on the way to listing on the public markets at a valuation of over $5 billion.
But with investors fast losing their appetite for technology stocks in recent months, the online drugs and medical services startup shelved its IPO in November. Now, some of the decisions it took in the run-up to the withdrawn public offer are beginning to bite. In particular, its acquisition of diagnostics chain Thyrocare in June 2021, which has become a millstone around its neck, threatening to thwart PharmEasy’s ambition to build India’s biggest …
Surendar helps lead the newsroom at The Morning Context as executive editor. Over the years, Surendar has worked in industries from pharmaceuticals to diamonds, as well as a stint as an equity analyst. In his long career as a business journalist, he has led teams at The Times of India, India Today and Fortune India. He was part of the founding team at Forbes India and interned at and published in The Times, London.
Executive Editor
surendar@mailtmc.com
Mumbai
Samiksha covered all things startups at The Morning Context. She joined us from The New Indian Express, where she wrote stories on the retail and food sectors. Prior to that, she had covered startups and written various business features in the Deccan Herald.
Writer
samiksha@mailtmc.com
Bengaluru